Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States.
The last earnings update was 18 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Cara Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Cara Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Cara Therapeutics's earnings are expected to grow significantly at over 20% yearly.
Cara Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Cara Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Cara Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Cara Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Cara Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Cara Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 28.9x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Derek T. Chalmers, Ph.D., D.Sc. co-founded Cara Therapeutics, Inc. in 2004 and has been its Chief Executive Officer and President since September 2004. Dr. Chalmers served as a Principal Investigator at Neurocrine Biosciences (Nasdaq; NBIX). He co-founded Arena Pharmaceuticals (Nasdaq: ARNA) in 1997. He served as Vice President of Research of Arena Pharmaceuticals Inc., from April 1997 to May 1, 2004. From 1994 to January 1997, he directed various research programs at Neurocrine. From 1990 to 1994, he was engaged in research at the University of Michigan. Dr. Chalmers has over 24 years of experience in the biotechnology industry with increasing levels of corporate and business responsibilities. He has extensive corporate financing experience, having led both private and IPO road-show teams. He is an inventor or co-inventor on 31 issued or pending US patents. He has been a Director at Cara Therapeutics, Inc. since July 2004. He served as an Executive Director of Arena Pharmaceuticals Inc., from April 2000 to May 2004 and its Vice President from June 1997 to May 2004. Dr. Chalmers holds a Ph.D. in Neuroscience and Neuropharmacology from the University of Glasgow, Scotland.
Derek's compensation has been consistent with company performance over the past year, both up more than 20%.
Derek's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Cara Therapeutics management team is less than 2 years, this suggests a new team.
Chief Scientific Officer and Senior VP of R&D
Chief Medical Officer
Co-Founder & Chief Scientific Advisor
CFO & Chief Strategy Officer
Chief Compliance Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Cara Therapeutics board of directors is about average.
Where Cara Therapeutics Inc (NASDAQ:CARA) Stands In Terms Of Earnings Growth Against Its Industry
Today I will assess CARA's recent performance announced on 31 March 2018 and weigh these figures against its long-term trend and industry movements. … Did CARA beat its long-term earnings growth trend and its industry … CARA is loss-making, with the most recent trailing twelve-month earnings of -US$52.69m (from 31 March 2018), which compared to last year has become
Cara Therapeutics Inc's (NASDAQ:CARA) Profit Outlook
Check out our latest analysis for Cara Therapeutics Expectation from analysts is CARA is on the verge of breakeven. … What rate will CARA have to grow year-on-year in order to breakeven on this date? … Should the business grow at a slower rate, it will become profitable at a later date than expected.
Cara Therapeutics Inc (NASDAQ:CARA): Did It Outperform The Industry?
After reading Cara Therapeutics Inc's (NASDAQ:CARA) latest earnings update (31 December 2017), I found it beneficial to look back at how the company has performed in the past and compare this against the most recent numbers. … View our latest analysis for Cara Therapeutics Was CARA's recent earnings decline indicative of a tough track record? … This means that whatever tailwind the industry is profiting from, Cara Therapeutics has not been able to leverage it as much as its industry peers.What does this mean?
Is Cara Therapeutics Inc (CARA) Thriving Or Barely Surviving In The Healthcare Sector?
The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. … Healthcare analysts are forecasting for the entire industry, a fairly unexciting growth rate of 6.42% in the upcoming year , and an enormous growth of 43.65% over the next couple of years. … In the past year, the industry delivered negative growth of -60.80%, underperforming the US market growth of 4.49%.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease (CKD) associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from chronic kidney disease-associated pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that is in Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; and in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.